Delcade Avocats & Solicitors, took part in the sale of the entire capital of RAL Diagnostics to CELLAVISION AB
Le October 21, 2019 Par Sabine VANDERSTRICHT
Paris, October 20, 2019 – Delcade Avocats & Solicitors, took part in the sale of the entire capital of RAL Diagnostics to CELLAVISION AB (Publ).
Delcade Avocats & Solicitors (Sophie Coignat, partner and Pierre Papelard, partner) advised the shareholders of the company RAL Diagnostics, a French company specializing in biological dyes in the medical and industrial sector, in the context of the sale of their shares in RAL Diagnostics to CellaVision AB (Publ), a Swedish listed company specializing in the medical technology sector, for an enterprise value of € 25 million.
RAL Diagnostics is positioned as a key player in the field of health and contributes to the innovation of In Vitro Diagnostics (IVD) by creating more efficient and environmentally friendly products.
CellaVision AB (Publ) was advised by FTPA Avocats (Nathalie Younan, partner, Johanna Grangier, associate) and the Swedish law firm Mannheimer Swartling (Per Asbrink, partner, Erik Hensfelt, associate)
Our latest news
Developing a Compliance Program
A checklist outlining the key steps to take and the main issues to consider when developing a compliance program, including overlaps with the environmental, social and governance (ESG) frameworkLire l'article
DELCADE welcomes Pierre-Antoine Dubecq as a Partner M&A and Private Equity
DELCADE is delighted to welcome Pierre-Antoine Dubecq as a partner in the Paris office.Lire l'article
Publishing of the first French Guidelines relating to the Control of Foreign Investments in France
Published on 8 September 2022, the French Guidelines on the Control of Foreign Investment in France sadly are an unfinished workLire l'article